We don't have tangible evidence that it has come back, but we certainly have a commitment from CAHI, which is coming in for pre-submission meetings.
One of the conversations we've had with CAHI through the advisory committee is about coming in very early during the drug development. If they come in early, if we are able to very clearly give them what our requirements are, if we provide them with clarity and guidance in the regulatory requirements, these studies will be done in Canada. And if these studies are being done in Canada, then that will bring R and D.
We are having that dialogue. It's in their best interest to be able to bring these particular products very early on. It will bring R and D and it will improve efficiency in terms of the approval process.